Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Histone deacetylase inhibitors.

Claude Monneret1

  • 1Laboratoire de pharmacochimie, unité mixte 176 CNRS/IC, Institut Curie, section de recherche 26, rue d'Ulm, 75248 Paris cedex 05, France. claude.monneret@curie.fr

European Journal of Medicinal Chemistry
|January 12, 2005
PubMed
Summary

Histone deacetylase (HDAC) inhibitors are a promising cancer therapy strategy. These compounds induce tumor cell apoptosis and growth arrest by regulating gene expression and chromatin assembly.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is an endocrine disruptor?

Comptes rendus biologies·2017
Same author

Doxorubicin conjugates for selective delivery to tumors.

Topics in current chemistry·2013
Same author

Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex.

Biochemistry·2011
Same author

Histone deacetylase inhibitors for epigenetic therapy of cancer.

Anti-cancer drugs·2007
Same author

Protecting groups for glucuronic acid: application to the synthesis of new paclitaxel (taxol) derivatives.

The Journal of organic chemistry·2006
Same author

Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides.

Nucleic acids research·2006

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Histones are basic proteins essential for packaging the human genome into chromatin.
  • Histone acetylation/deacetylation, regulated by histone acetylases and histone deacetylases (HDACs), is crucial for gene expression.
  • HDAC inhibition is a novel cancer therapy approach due to its role in tumor cell growth arrest, differentiation, and apoptosis.

Purpose of the Study:

  • To review the development and therapeutic potential of histone deacetylase (HDAC) inhibitors in cancer treatment.
  • To highlight the evolution of HDAC inhibitor design from natural products to synthetic analogs.
  • To discuss the clinical progression of various HDAC inhibitors.

Main Methods:

  • Review of existing literature on HDACs, their biological functions, and therapeutic applications.
  • Analysis of the structural evolution of HDAC inhibitors, including natural products and synthetic compounds.
  • Summary of clinical trial data for notable HDAC inhibitors.

Main Results:

  • Natural HDAC inhibitors often exhibit instability and low retention in vivo.
  • Synthetic HDAC inhibitors, such as those with hydroxamic acid or benzamide structures, show improved efficacy.
  • Several synthetic HDAC inhibitors (e.g., LAQ824, PDX101, MS-275, CI-994) are progressing through clinical trials.

Conclusions:

  • HDAC inhibitors represent a significant advancement in cancer therapy.
  • Structural modifications have led to more potent and stable HDAC inhibitors.
  • Ongoing clinical trials are evaluating the efficacy and safety of novel HDAC inhibitors for cancer treatment.

Related Experiment Videos